---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134812"
form_type: "8-K"
ticker: null
cik: "0001962918"
company_name: "ACELYRIN, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:18:20.054252+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ACELYRIN appoints Mina Kim as CEO; founder Lin steps down; cash $678.5M

## Summary
- Mina Kim appointed CEO and board member effective May 9; Shao-Lee Lin steps down as CEO and from board.
- Cash, cash equivalents and short-term marketable securities total $678.5M at March 31, 2024; funding into 2026 reiterated.
- Izokibep Phase 3 HS trial enrollment completed (258 patients); top-line data expected Q3 2024.
- Positive proof-of-concept for lonigutamab in thyroid eye disease; Phase 2b/3 trial planned H2 2024.
- Company will not host Q1 2024 earnings call; 10-Q to be filed by May 14, 2024.

## SEC filing metadata
- accession: 0001193125-24-134812
- form_type: 8-K
- cik: 0001962918
- company_name: ACELYRIN, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/0001193125-24-134812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/d799182d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134812
- JSON: https://secwatch.observer/filing/0001193125-24-134812.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134812.txt

## Key facts
- Executive change
  Ron Oyston departed as Chief People Officer at ACELYRIN, Inc..
  - Action: stepped down
  - Role: Chief People Officer
  source text: Effective on May 8, 2024, the Company and Ron Oyston mutually agreed that Mr. Oyston will step down from his position as Chief People Officer, effective August 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/0001193125-24-134812-index.htm
- Executive change
  Mina Kim was appointed as Chief Executive Officer at ACELYRIN, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Effective May 9, 2024, Mina Kim was appointed as the Chief Executive Officer of the Company and was appointed as a member of the Board of Directors of the Company (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/0001193125-24-134812-index.htm
- Executive change
  Shao-Lee Lin departed as Chief Executive Officer at ACELYRIN, Inc..
  - Action: stepped down
  - Role: Chief Executive Officer
  source text: By mutual agreement of Shao-Lee Lin, M.D., Ph.D. and the Company, Dr. Lin stepped down from her position as Chief Executive Officer and as a member of the Board, effective on May 8, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/0001193125-24-134812-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.